drugset / Trial / NCT05521802
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label study to evaluate the safety and efficacy of C-CAR088 in patients with relapsed or refractory multiple myeloma. The phase Ib part of this study is to determine the recommended phase 2 dose (RP2D) of C-CAR088 in the targeted patient population.
Timeline
- Start
- 2022-11-11
- Primary completion
- 2024-07
- Completion
- 2037-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C-CAR088 | Cell therapy | — | Intravenous |